Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 17, Number 12—December 2011

Letter

Porcine and Human Community Reservoirs of Enterococcus faecalis, Denmark

Jesper LarsenComments to Author , Henrik C. Schønheyder, Kavindra V. Singh, Camilla H. Lester, Stefan S. Olsen, Lone J. Porsbo, Lourdes Garcia-Migura, Lars B. Jensen, Magne Bisgaard, Barbara E. Murray, and Anette M. Hammerum
Author affiliations: Statens Serum Institut, Copenhagen, Denmark (J. Larsen, C.H. Lester, S.S. Olsen, A.M. Hammerum); Aarhus University Hospital, Aalborg, Denmark (H.C. Schønheyder); University of Texas Medical School, Houston, TX, USA (K.V. Singh, B.E. Murray); Technical University of Denmark, Søborg, Denmark (L.J. Porsbo); Technical University of Denmark, Kgs. Lyngby, Denmark (L. Garcia-Migura, L.B. Jensen); University of Copenhagen, Frederiksberg, Denmark (M. Bisgaard)

Main Article

Table A1

Origins and molecular and phenotypic characteristics of Enterococcus faecalis isolates*

ID (other name) Origin† Setting Sampling
year MLST† PFGE‡ Biofilm formation Virulence-associated genes PAI genes Resistance profile
31438-1 IE patient HA 1997 97 A Weak ebpA gelE hylA ef1896 ef2505 ace cbh None
130529 IE patient HA 2000 97 A Weak ebpA gelE hylA ef1896 ef2505 ace cbh None
67190 IE patient CA 2002 97 A Weak ebpA gelE hylA ef1896 ef2505 ace cbh None
7330616-3 (D30) Pig NA 2001 97 A Weak ebpA gelE hylA ef1896 ef2505 ace cbh None
28137 IE patient HA 1996 72 B None ebpA gelE ef1824 hylA ef2505 hlyB ace cbh None
7684 IE patient HA 1997 72 B Weak ebpA gelE ef1824 hylA ef2505 hlyB ace cbh None
33873 IE patient HA 2002 72 B Medium ebpA gelE ef1824 hylA ef2505 hlyB ace cbh None
1293 CD human NA 2003 72 B Medium ebpA gelE ef1824 hylA ef2505 hlyB ace cbh None
3527 CD human NA 2006 72 B Medium ebpA gelE ef1824 hylA ef2505 hlyB ace cbh None
1745 CD human NA 2004 72 U1 Weak ebpA gelE ef1824 hylA ef2505 hlyB ace cbh TET
43674 IE patient CA 1999 19 C Medium ebpA gelE ef2505 hlyB ace None ERY TET
2247 CD human NA 2004 19 C Medium ebpA gelE ef2505 hlyB ace cbh esp CIP ERY TET
54869 IE patient HA 1997 40 D Weak ebpA gelE hylA ef2505 hlyB ace cbh KAN STR TET
7330082-2 (D1) Pig NA 2001 40 D Medium ebpA gelE hylA ef2505 hlyB ace cbh esp None
7330321-1 (D27) Pig NA 2001 40 D Medium ebpA gelE hylA ef2505 hlyB ace cbh esp CHL ERY KAN STR TET
7331063-5 (D37) Pig NA 2001 40 D None ebpA gelE hylA ef2505 hlyB ace cbh STR
7330887-1 (D32) Pig NA 2001 40 U2 None ebpA gelE hylA ef2505 hlyB ace cbh ERY STR
26669 IE patient HA 1998 21 E Weak ebpA gelE hylA ef2505 hlyB ace cbh None
3162 CD human NA 2005 21 E Weak ebpA gelE hylA ef2505 ace cbh esp TET
105049 IE patient CA 1997 306 E Medium ebpA gelE hylA ef1896 ef2505 ace cbh esp None
127801 IE patient CA 1999 306 F Medium ebpA gelE hylA ef1896 ef2505 ace cbh esp None
2421 CD human NA 2004 306 F Medium ebpA gelE hylA ef1896 ef2505 ace cbh esp None
57690 IE patient HA 2000 22 NA Weak ebpA gelE ef1824 hylA ef2505 hlyB ace cbh None
20505-1 IE patient HA 2000 30 NA Weak ebpA gelE hylA ef1896 ef2505 ace esp TET
100087 IE patient HA 1999 41 NA Weak ebpA gelE hylA ef1896 ef2505 ace cbh esp ERY KAN STR TET
105158 IE patient HA 1997 55 NA Medium ebpA hylA ef1896 ef2505 hlyB ace cbh esp CHL ERY KAN STR TET
134125 IE patient HA 2000 55 NA Strong ebpA hylA ef1896 ef2505 hlyB ace cbh esp CHL ERY KAN STR TET
29783 IE patient HA 1999 81 NA Medium ebpA gelE ef1824 hylA ef2505 hlyB ace cbh ef0571 None
120903 IE patient CA 1999 192 NA Medium ebpA gelE ef1824 hylA ef2505 hlyB ace None TET
107137 IE patient HA 2001 241 NA Weak ebpA gelE ef1824 hylA ef2505 hlyB ace cbh ef0571 None
83232 IE patient CA 1997 326 NA Strong ebpA gelE hylA ef1896 ef2505 ace cbh esp None
1149 CD human NA 2003 133 NA Strong ebpA hylA ef1896 ef2505 ace cbh TET
3392 CD human NA 2005 133 NA Medium ebpA hylA ef1896 ef2505 ace cbh None
1732 CD human NA 2003 141 NA None ebpA gelE ef1824 hylA ef2505 hlyB ace None CIP
1028 CD human NA 2003 168 NA Strong ebpA gelE ef1824 hylA ef2505 hlyB ace cbh None
1309 CD human NA 2003 168 NA Strong ebpA gelE ef1824 hylA ef2505 hlyB ace cbh None
1413 CD human NA 2003 199 NA Medium ebpA gelE ef1824 hylA ef2505 ace cbh None
2174 CD human NA 2004 206 NA Weak ebpA hylA ef2505 ace cbh TET
2041 CD human NA 2004 327 NA Weak ebpA hylA ef2505 ace cbh TET

*MLST, multi-locus sequence typing; PFGE, pulsed-field gel electrophoresis; PAI, pathogenicity island; IE, infective endocarditis; CD, community-dwelling; HA, healthcare-associated infection; CA, community-acquired infection; NA, not applicable; CHL, chloramphenicol; CIP, ciprofloxacin; ERY, erythromycin, KAN, kanamycin; STR, streptomycin; TET, tetracycline.
†STs from 5 pig isolates (in italics) have been published previously (7); the remaining 14 pig isolates belonging to other STs (ST1, ST6, ST16, ST26, ST47, ST63, ST96, ST98, ST99, and ST100) were not included in further analysis.
‡Isolates with similar PFGE banding patterns (>82% relatedness) received the same letter designation (A–F) to reflect their genetic relatedness; highly divergent PFGE banding patterns were designated as unique (U) types (U1 and U2).

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO